H2020Индивидуална стипендия2019–2023

BioSMaLL · Biopolymers for the Generation of 3D Tissue Engineering Scaffolds by Solution Mask Liquid Lithography

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2019-07-01 → 2023-11-30
Финансиране от ЕС: 257 561 €
Участници: 2
Схема: MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Полипептидните хидрогели и 3D принтирането чрез течна литография се изследват за създаване на структури за възстановяване на хрущялни тъкани. Това е важно, защото настоящите материали имат ниска механична здравина, а много хора страдат от проблеми с опорно-двигателния апарат.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Biopolymers for the Generation of 3D Tissue Engineering Scaffolds by Solution Mask Liquid Lithography

Musculoskeletal conditions reduce the quality of life of many adults worldwide, with the WHO citing that up to 1.71 billion people are affected. Lower back injury is a prevailing issue, suffered by nearly 568 million people. As the joint cartilage breaks down, inflammation/pain causes poor mobility and dexterity for patients, sometimes needing surgical intervention. The continued burden on healthcare professionals is to come up with a viable treatment solution, and cartilage regeneration is of particular interest. This demand for a pragmatic solution has prompted the investigation of biomaterials, which are a class of synthetically optimised biocompatible polymers, which promote low to no toxicity within humans. Hydrogels are highly hydrated, soft materials, which are highly explored as biomaterials in biomedicine. Continued research efforts into biomaterial hydrogel development has led to many promising studies on their use as biocompatible 3D implantable or injectable augments for cartilage regeneration, albeit in academic settings. These studies may provide solutions to current healthcare issues surrounding impact or wear and tear injuries that damage cartilage, by replacing existing treatments such as mosaicplasty, an autologous cartilage transplant – which isn’t always successful in patients. However, current biomaterial hydrogels have limitations, including material reproduction issues and poor mechanical strength. Newer tailored made materials with improved properties for cartilage regeneration are of significant interest – with polypeptide hydrogels of note and representing high promise in biomedicine. Coupling tailor made polypeptide materials and cell components with a low-cost technology for 3D printing objects, namely Solution Mask Liquid Lithography (SMaLL) – a digital light processing (DLP) method, 3D biomedical scaffolds may be realised. This project aims to provide new hydrogel material platform(s) for potential clinical translation with 3 overlapping objectives: 1. Development of synthetically simplified polypeptide hydrogels that can be reproduced on demand. 2. The use of these hydrogels as viable growth matrices for mammalian cells with a focus on cartilage regeneration. 3. Enabling 3D object development with this hydrogel/cell blend using a custom DLP 3D printer.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Three-dimensional (3D) printing in biomedical science has recently advanced the development of tailor-made implants. Designing structural and functional 3D constructs mimetic of both tissues and organs offers a genuine route to personalised implants, improving the patients' quality of life and reducing healthcare costs. While engineers have significantly progressed 3D printing methods, the barriers to progress include the limited variety of printable materials as well as the need for alternative low-cost printing technologies. BioSMaLL aims to address this through combining Solution Mask Liquid Lithography (SMaLL), a recent technology developed at the University of California Santa Barbara (UCSB), with the expertise of the applicant and the Royal College of Surgeons in Ireland (RCSI) in functional biopolymers and tissue engineering to develop bio-active scaffolds. The objectives of this global fellowship will be achieved by adaptation of BioSMaLL for newly designed biopolymers during the outgoing phase at UCSB . In a transfer of knowledge, BioSMaLL will then be established at RCSI and bespoke biocompatible scaffolds produced and validated during the incoming phase. The innovative approach will be facilitated by an interdisciplinary methodology at the interface of polymer chemistry, (bio)materials science, 3D printing and tissue engineering in two world-renowned groups. The career goal of the fellow to embark on a career in emerging biomedical technologies in a start-up company will be facilitated by a dedicated training programme across scientific methods as well as complementary training at UCSB and RCSI covering leadership, project management and commercialisation in addition to meetings with laboratory and management staff of the start-up company SurgaColl. The partners have a proven track record in training future leaders in materials science and healthcare aiming to make a difference and establish new technologies and innovative processes in Europe and beyond.

Оригинален текст от CORDIS (на английски).

Участници

ROYAL COLLEGE OF SURGEONS IN IRELAND · DUBLIN 2КоординаторИрландия
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA · OaklandСъединени щати